CD40-CD40 Ligand-Independent Activation of CD8+T Cells Can Trigger Allograft Rejection-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD40-CD40 Ligand-Independent Activation of CD8+T Cells Can Trigger Allograft Rejection

Published:2000-07-15 Issue:2 Volume:165 Page:1111-1118
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J Immunol

Author:

Jones Nick D.,Van Maurik Andre,Hara Masaki,Spriewald Bernd M.,Witzke Oliver,Morris Peter J.,Wood Kathryn J.

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference56 articles.

1. Molecular and biological characterization of a murine ligand for CD40

2. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity.

3. Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes

4. CD40 ligand-positive CD8+ T cell clones allow B cell growth and differentiation

5. Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects;Pharmaceuticals;2023-06-25

2. Gut microbes enlarged the protective effect of transplanted regulatory B cells on rejection of cardiac allografts;The Journal of Heart and Lung Transplantation;2021-12

3. Invariant NKT Cells Promote the Development of Highly Cytotoxic Multipotent CXCR3+CCR4+CD8+ T Cells That Mediate Rapid Hepatocyte Allograft Rejection;The Journal of Immunology;2021-11-22

4. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy;Advances in Cancer Research;2019

5. Characterization of eomesodermin and T-bet expression by allostimulated CD8+ T cells of healthy volunteers and kidney transplant patients in relation to graft outcome;Clinical and Experimental Immunology;2018-09-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3